Speech-Language Pathologists in Lexington, TN Accepting Medicare

6 Speech-Language Pathologists found. Showing 1 - 6

Douglas R Mays, SLP/CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 112 Airways Dr, Lexington, TN 38351 Phone: 423-622-1551    Fax: 423-622-1556

Holli Helms, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 41 Hospital Dr, Lexington, TN 38351 Phone: 731-968-6629

Mrs. Angie Dawn Brasher, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 727 E Church St, Lexington, TN 38351 Phone: 731-968-2004

Kara Edwards, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 727 E Church St, Lexington, TN 38351 Phone: 731-968-2004

Amber Carmichael Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 9550 Highway 412 W Ste A, Lexington, TN 38351 Phone: 731-967-3224

Hillary Overbey, SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 9550 Highway 412 W Ste A, Lexington, TN 38351 Phone: 731-967-3224    Fax: 731-967-3305

News Archive

Look AHEAD intervention program improves risk factors in obese, type 2 diabetic patients

An intensive lifestyle intervention program designed to achieve and maintain weight loss improves diabetes control and cardiovascular disease risk factors in overweight and obese individuals with type 2 diabetes, according to four-year results of the Look AHEAD study, funded by the National Institutes of Health and the Centers for Disease Control and Prevention. The results are published in the Sept. 27, 2010, issue of the Archives of Internal Medicine.

Study highlights importance of students' beliefs for their academic progress

Research on how junior high school students' beliefs about intelligence affect their math grades found that those who believed that intelligence can be developed performed better than those who believed intelligence is fixed.

Celldex announces final results from CDX-011 Phase 2b study on GPNMB-expressing breast cancer

Celldex Therapeutics, Inc. today announced final results from the Company's randomized Phase 2b EMERGE study of CDX-011 in patients with glycoprotein NMB (GPNMB)-expressing, advanced, heavily pretreated breast cancer.

Vaccinex and Biocon to co-develop at least four therapeutic antibody products

The collaboration combines Vaccinex's unique capabilities to discover fully human monoclonal antibodies using its proprietary antibody discovery technology and Biocon's proven expertise in clinical research and biologics manufacturing.

Research looks at convalescent plasma use in COVID-19 mouse model

A new study by researchers at the University of Iowa and published on the preprint server bioRxiv in August 2020 reports the utility of a mouse model that recapitulates several aspects of human COVID-19 and can reflect the antiviral efficacy of new drugs as well.

Read more Medical News

› Verified 6 days ago